Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,327Revenue $M45.6Net Margin (%)-492.2Z-Score-2.4
Enterprise Value $M1,375EPS $-1.5Operating Margin %-483.4F-Score2
P/E(ttm))0Cash Flow Per Share $-0.8Pre-tax Margin (%)-491.0Higher ROA y-yY
Price/Book16.510-y EBITDA Growth Rate %0Quick Ratio4.0Cash flow > EarningsY
Price/Sales29.55-y EBITDA Growth Rate %0Current Ratio4.0Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-55.0Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)3ROE % (ttm)-146.5Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M187ROI % (ttm)-83.9Gross Margin Increase y-yN

Gurus Latest Trades with ARIA

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ARIAGeorge Soros 2014-09-30 Reduce-0.04%$5.01 - $6.5
($5.84)
$ 7.0921%Reduce -85%150,000
ARIAGeorge Soros 2014-06-30 Add0.02%$6.3 - $8.52
($6.89)
$ 7.093%Add 100%1,000,000
ARIAGeorge Soros 2014-03-31 Reduce-0.08%$6.46 - $8.99
($7.75)
$ 7.09-8%Reduce -74.36%500,000
ARIAGeorge Soros 2013-12-31 Buy 0.11%$2.2 - $18.8
($5.16)
$ 7.0937%New holding, 1950000 sh.1,950,000
ARIADaniel Loeb 2013-06-30 Sold Out -0.94%$16.32 - $19.77
($17.73)
$ 7.09-60%Sold Out0
ARIADaniel Loeb 2012-12-31 Add0.4%$18.93 - $25.16
($22.12)
$ 7.09-68%Add 85.19%2,500,000
ARIAAndreas Halvorsen 2012-12-31 Sold Out -0.33%$18.93 - $25.16
($22.12)
$ 7.09-68%Sold Out0
ARIAAndreas Halvorsen 2012-09-30 Buy 0.33%$17.11 - $24.21
($19.85)
$ 7.09-64%New holding, 1934500 sh.1,934,500
ARIADaniel Loeb 2012-09-30 Reduce-0.39%$17.11 - $24.21
($19.85)
$ 7.09-64%Reduce -35.71%1,350,000
ARIADaniel Loeb 2012-06-30 Buy 1.1%$14.6 - $17.82
($16.35)
$ 7.09-57%New holding, 2100000 sh.2,100,000
ARIAGeorge Soros 2012-06-30 Sold Out -0.15%$14.6 - $17.82
($16.35)
$ 7.09-57%Sold Out0
ARIAGeorge Soros 2012-03-31 Buy 0.15%$12.73 - $16.32
($13.74)
$ 7.09-48%New holding, 635000 sh.635,000
ARIAGeorge Soros 2011-12-31 Sold Out -0.07%$8.03 - $12.5
($10.96)
$ 7.09-35%Sold Out0
ARIAGeorge Soros 2011-09-30 Buy 0.07%$7.63 - $13.34
($10.54)
$ 7.09-33%New holding, 496847 sh.496,847
ARIAJean-Marie Eveillard 2008-06-30 Buy $2.39 - $3.57
($2.8)
$ 7.09153%New holding, 50000 sh.50,000
ARIAGeorge Soros 2008-06-30 Sold Out -0.01%$2.39 - $3.57
($2.8)
$ 7.09153%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARIA is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
ARIA George Soros 2014-09-30150,0000.080.01-85%
Premium Most recent portfolio changes are included for Premium Members only!


ARIA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BERGER HARVEY J M DChairman & CEO 2014-12-18Buy25,000$6.358.19view
Schlesinger Sarah J.Director 2014-12-17Buy2,600$6.0912.81view
Cantor Maria ESVP, Corporate Affairs and HR 2014-11-24Sell1,749$7-1.86view
BERGER HARVEY J M DChairman & CEO 2014-11-20Buy25,000$6.1511.71view
Schlesinger Sarah J.Director 2014-11-12Buy2,600$6.269.74view
BERGER HARVEY J M DChairman & CEO 2014-10-16Buy25,000$5.2431.11view
Schlesinger Sarah J.Director 2014-10-15Buy2,600$5.0536.04view
Schlesinger Sarah J.Director 2014-09-10Buy5,200$5.7319.9view
BERGER HARVEY J M DChairman & CEO 2014-09-03Buy25,000$6.279.57view
BERGER HARVEY J M DChairman & CEO 2014-09-03Buy25,000$6.279.57view

Press Releases about ARIA :

    Quarterly/Annual Reports about ARIA:

    News about ARIA:

    Articles On GuruFocus.com
    Sarah Ketterer of Causeway Capital's Answers to GuruFocus Q&A Apr 07 2014 
    Weekly CEO Sells Highlight: U.S. Bancorp, Restoration Hardware Holdings Inc, Ariad Pharmaceuticals, Jul 20 2013 
    Daniel Loeb's Top Three Increases of the First Quarter May 24 2013 
    comment on ARIA Mar 15 2013 
    comment on ARIA Mar 15 2013 
    comment on ARIA May 16 2012 
    Weekly CFO Sales Highlight: WWWW, FIO, CRIS, ARIA, VOG, APKT Apr 22 2012 
    3 Biotech Stocks To Consider Buying Right Now Jan 10 2012 
    ARIAD Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
    creiter note on ARIA Jan 03 2010 

    More From Other Websites
    Ariad nabs $77.5 million in licensing pact Dec 23 2014
    ARIAD and Otsuka Announce Co-Development and Commercialization Agreement for Iclusig to Treat... Dec 23 2014
    ARIAD and Otsuka Announce Co-Development and Commercialization Agreement for Iclusig to Treat... Dec 23 2014
    ARIAD To Present at The 33rd Annual J.P. Morgan Healthcare Conference Dec 22 2014
    ARIAD To Present at The 33rd Annual J.P. Morgan Healthcare Conference Dec 22 2014
    Adam Feuerstein's 2014 Biotech Stock Report Card (No Grading on a Curve) Dec 19 2014
    ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 11 2014
    Mid-Morning Market Update: Markets Surge; Lululemon Profit Beats Expectations Dec 11 2014
    Will Ariad Pharmaceuticals (ARIA) Stock be Affected Today by This Analyst Action? Dec 11 2014
    Analysts' Actions: AbbVie, Ariad, Lilly, Prologis, Toll Brothers Dec 11 2014
    UPDATE: Credit Suisse Downgrades Ariad Pharmaceuticals As Launch Metrics Are Still Weak Dec 11 2014
    ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib in Chronic-Phase Chronic Myeloid... Dec 09 2014
    ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib in Chronic-Phase Chronic Myeloid... Dec 09 2014
    ARIAD Announces Follow-up Data from Phase 1 and PACE Trials of Ponatinib in Patients with T315I... Dec 09 2014
    ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial Dec 08 2014
    ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial Dec 08 2014
    Ariad Pharmaceuticals (ARIA) Jumps: Stock Gains 9.7% Nov 25 2014
    ARIAD Pharmaceuticals (ARIA) Strong On High Relative Volume Today Nov 24 2014
    ARIAD and STA Announce Approval of Iclusig (Ponatinib) in Australia Nov 24 2014
    ARIAD and STA Announce Approval of Iclusig (Ponatinib) in Australia Nov 24 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK